AstraZeneca COVID drug neutralizes Omicron sub-variants in study, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

AstraZeneca said its antibody-based cocktail to prevent and treat COVID-19 was shown to retain neutralising activity against Omicron coronavirus variants, including the highly contagious BA.2 sub-variant, in an independent lab study., AstraZeneca said its antibody-based cocktail to prevent and treat COVID-19 was shown to retain neutralising activity against Omicron coronavirus variants, including the highly contagious BA.2 sub-variant, in an independent lab study., , Read More